Publications

2021

Gill J, Gorlick R. Advancing therapy for osteosarcoma. Nat Rev Clin Oncol. 2021 Jun 15. doi: 10.1038/s41571-021-00519-8. Online ahead of print.PMID: 34131316 

Nevil G, Roth M, Gill J, Zhang W, Teicher B, Erickson SW, Gatto G, Smith M, Kolb EA, Gorlick R. Initial in vivo testing of TPO-receptor agonist eltrombopag in osteosarcoma patient-derived xenograft models by the pediatric preclinical testing consortium. Pediatr Hematol Oncol. 2021 Feb;38(1):8-13. doi: 10.1080/08880018.2020.1802539. Epub 2020 Aug 17.PMID: 32804009

Hingorani P, Roth ME, Wang Y, Zhang W, Gill JB, Harrison DJ, Teicher B, Erickson S, Gatto G, Smith MA, Kolb EA, Gorlick R. ABBV-085, Antibody-Drug Conjugate Targeting LrRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium. Mol Cancer Ther. 2021 Mar;20(3):535-540. doi: 10.1158/1535-7163.MCT-20-0406. Epub 2020 Dec 9.PMID: 33298592 

Lamhamedi-Cherradi SE, Mohiuddin S, Mishra DK, Krishnan S, Velasco AR, Vetter AM, Pence K, McCall D, Truong DD, Cuglievan B, Menegaz BA, Utama B, Daw NC, Molina ER, Zielinski RJ, Livingston JA, Gorlick R, Mikos AG, Kim MP, Ludwig JA. Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in  human osteosarcoma. Cancer Gene Ther. 2021 Jan 6. doi: 10.1038/s41417-020-00281-6. Online ahead of print.PMID: 33408328

Zvi Y, Ugur E, Batko B, Gill J, Roth M, Gorlick R, Hall D, Tingling J, Barkauskas DA, Zhang J, Yang R, Hoang BH, Geller DS. Prognostic and Therapeutic Utility of Variably Expressed Cell Surface Receptors in Osteosarcoma. Sarcoma. 2021 Feb 2;2021:8324348. doi: 10.1155/2021/8324348. eCollection 2021.PMID: 33603563

2020

Kinnaman MD, Zhu C, Weiser DA, Mohiuddin S, Hingorani P, Roth M, Gill J, Janeway KA, Gorlick R, Lessnick SL, Grohar PJ. Survey of Paediatric Oncologists and Pathologists regarding Their Views and Experiences with Variant Translocations in Ewing and Ewing-Like Sarcoma: A Report of the Children’s Oncology Group. Sarcoma. 2020 Dec 5;2020:3498549. doi: 10.1155/2020/3498549. eCollection 2020.PMID: 33488267

Gill J, Hingorani P, Roth M, Gorlick R. HER2-Targeted Therapy in Osteosarcoma. Adv Exp Med Biol. 2020;1257:55-66. doi: 10.1007/978-3-030-43032-0_5.PMID: 32483730

Gill J, Zhang W, Zhang Z, Roth M, Harrison DJ, Rowshan S, Erickson S, Gatto G, Kurmasheva R, Houghton P, Teicher B, Smith MA, Kolb EA, Gorlick R. Does-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium. Pediatr Blood Cancer. 2020 Oct;67(10):e28606. doi: 10.1002/pbc.28606. Epub 2020 Jul 24.PMID: 32706456

Harrison DJ, Gill JD, Roth ME, Zhang W, Teicher B, Erickson S, Gatto G, Kurmasheva RT, Houghton PJ, Smith MA, Kolb EA, Gorlick R. Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium. Pediatr Blood Cancer. 2020 Jun;67(6):e28222. doi: 10.1002/pbc.28222. Epub 2020 Mar 24.PMID: 32207565

2019

Currier AW, Kolb EA, Gorlick RG, Roth ME, Gopalakrishnan V, Sampson VB. P27/Kip1 functions as a tumor suppressor and oncoprotein in osteosarcoma. Sci Rep. 2019 Apr 16;9(1):6161. doi: 10.1038/s41598-019-42450-0.

Geller DS, Levine NL, Hoang BH, Yang R, Weiser D, Morris J, Gorlick R, Gill JB, Roth ME, Tingling J, Brohl AS. Genomic Analysis Does Not Support Malignant Transformation of Osteoblastoma to Osteosarcoma. JCO Precis Oncol. 2019 Sep 9;3:PO.19.00166. doi: 10.1200/PO.19.00166. eCollection 2019.PMID: 32914027

Zhao Q, Hu J, Mitra A, Cutrera J, Zhang W, Zhang Z, Yan J, Xia X, Mahadeo KM, Livingston JA, Gorlick R, Li S. Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile. J Immunother Cancer. 2019 Jun 17;7(1):154. doi: 10.1186/s40425-019-0631-z.PMID: 31208461

Levine NL, Zhang Y, Hoang BH, Yang R, Jurkowski ZH, Roth ME, Gill JB, Lo Y, Eisenberg RE, Bekarev M, Gorlick R, Geller DS. LigaSure Use Decreases Intraoperative Blood Loss Volume and Blood Transfusion Volume in Sarcoma Surgery. J Am Acad Orthop Surg. 2019 Nov 15;27(22):841-847. doi: 10.5435/JAAOS-D-18-00144.PMID: 30889038

2018 

Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 2018 Jan;18(1):39-50. doi: 10.1080/14737140.2018.1413939. Epub 2017 Dec 14.PMID: 29210294 

Ferrari A, Gasparini P, Gill J, Gorlick R. Challenges of Clinical Management of Adolescent and Young Adults With Bone and Soft Tissue Sarcoma. Cancer J. 2018 Nov/Dec;24(6):301-306. doi: 10.1097/PPO.0000000000000337.PMID: 30480574 

Shaul E, Roth M, Lo Y, Geller DS, Hoang B, Yang R, Malkin D, Gorlick R, Gill J. Pediatric oncologist willingness to offer germline TP53 testing in osteosarcoma. Cancer. 2018 Mar 15;124(6):1242-1250. doi: 10.1002/cncr.31212. Epub 2018 Jan 3.PMID: 29313943 

Zhu C, Olson KA, Roth M, Geller DS, Gorlick RG, Gill J, Laack NN, Randall RL. Provider views on the management of Ewing sarcoma of the spine and pelvis. J Surg Oncol. 2018 Mar;117(3):417-424. doi: 10.1002/jso.24860. Epub 2017 Oct 16.PMID: 29044582

Weiner S, Barris D, Dubin R, Fremed M, Zhang Z, Piperdi S, Zhang W, Maqbool S, Gill J, Roth M, Hoang B, Geller D, Gorlick R, Wesier D. Detection of Circulating Tumor DNA in Patients with Osteosarcoma. Oncotarget. 19;9(16):12695-12704. 1/18. PMCID PMC5849166

Zhang Y, Zvi YS, Batko B, Zaphiros N, O'Donnell EF, Wang J, Sato K, Yang R, Geller DS, Koirala P, Zhang W, Du X, Piperdi S, Liu Y, Zheng D, Roth M, Gill J, Zhang J, Ren T, Gorlick R, Zi X, Hoang BH. Down-regulation of Skp2 expression inhibits invasion and lung metastasis in osteosarcoma. Sci Rep. 2018 24;8(1):14294. PMID: 30250282.

2017

Ren T, Piperdi S, Koirala P, Park A, Zhang W, Ivenitsky D, Zhang Y, Villanueva-Siles E, Hawkins D, Roth M, Gorlick R. CD49b inhibits Osteogenic differentiation and plays an important role in osteosarcoma progression. Oncotarget. 23;8(5):87848-59 E-Pub 10/2017. PMCID: PMC5675677

Morris J, Gill J, Connolly P, Roth M, Chung S, Zhang W, Piperdi S, Hoang B, Yang R, Guzik H, Gorlick R, Geller D. The effect of bone morphogenetic protein-2 on osteosarcoma metastasis. Plos One 12(3), 3/2017. E-Pub 3/2017. PMCID: PMC5338793

Yang Y, Yang R, Roth M, Piperdi S, Zhang E, Dorfman H, Rao P, Park A, Tripathi S, Rosenblum J, Geller D, Hoang B, Gill J, Gorlick R. Genetically Transforming Osteoblasts to Sarcoma: Development of an Osteosarcoma Model. Genes and Cancer (1-2):484-494, 1/2017. E-Pub 1/2017. PMCID: PMC5396624.

Kurmasheva RT, Gorlick R, Kolb EA, Keir ST, Maris JM, Lock RB, Carol H, Kang M, Reynolds CP, Wu J, Houghton PJ, Smith MA. Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 64(4), 4/2017. e-Pub 10/2016. PMID: 27786412

Lock R, Carol H, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Wu J, Purmal A, Gudkov A, Kurmashev D, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. Pediatr Blood Cancer 64(4), 4/2017. e-Pub 9/2016. PMID: 27650817.

2016

Koirala P, Roth ME, Gill J, Chinai JM, Ewart MR, Piperdi S, Geller DS, Hoang BH, Fatakhova YV, Ghorpade M, Zang X, Gorlick R. HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival. Sci Rep 6:31154, 8/2016. e-Pub 8/2016. PMCID: PMC4987662.

Geller DS, Morris J, Revskaya E, Kahn M, Zhang W, Piperdi S, Park A, Koirala P, Guzik H, Hall C, Hoang B, Yang R, Roth M, Gill J, Gorlick R, Dadachova E. Targeted therapy of osteosarcoma with radiolabeled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R). Nucl Med Biol 43(12):812-817, 12/2016. e-Pub 7/2016. PMCID: PMC5118104.

Koirala P, Roth ME, Gill J, Piperdi S, Chinai JM, Geller DS, Hoang BH, Park A, Fremed MA, Zang X, Gorlick R. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci Rep 6:30093, 7/2016. e-Pub 7/2016. PMCID: PMC4960483.

Sampson VB, Vetter NS, Zhang W, Patil PU, Mason RW, George E, Gorlick R, Kolb EA. Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma. Oncotarget. e-Pub 11/2016. PMID: 27863409.

Kang MH, Reynolds CP, Kolb EA, Gorlick R, Carol H, Lock R, Keir ST, Maris JM, Wu J, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA. Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 63(10):1744-52, 10/2016. e-Pub 5/2016. PMID: 27238606.

Murphy B, Yin H, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Kurmasheva RT, Dvorchik I, Wu J, Billups CA, Boateng N, Smith MA, Lock RB, Houghton PJ. Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis. Cancer Res 76(19):5798-5809, 10/2016. e-Pub 8/2016. PMCID: PMC5050128.

Gorlick R, Kolb EA, Keir ST, Maris JM, Lock RB, Carol H, Reynolds CP, Kang MH, Billups CA, Collins J, Kurmashev D, Kurmasheva RT, Houghton PJ, Smith MA. Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 63(3):443-50, 3/2016. e-Pub 11/2015. PMCID: PMC4724638.

Attiyeh EF, Maris JM, Lock R, Reynolds CP, Kang MH, Carol H, Gorlick R, Kolb EA, Keir ST, Wu J, Landesman Y, Shacham S, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA. Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. Pediatr Blood Cancer 63(2):276-86, 2/2016. e-Pub 9/2015. PMCID: PMC4722540.

2015

Roth M, Barris DM, Piperdi S, Kuo V, Everts S, Geller D, Houghton P, Kolb EA, Hawthorne T, Gill J, Gorlick R. Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma. Pediatr Blood Cancer 63(1):32-8, 1/2016. e-Pub 8/2015. PMID: 26305408.

Poon VI, Roth M, Piperdi S, Geller D, Gill J, Rudzinski ER, Hawkins DS, Gorlick R. Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma. Clin Sarcoma Res 5(1):4, 2015. e-Pub 1/2015. PMCID: PMC4311500.

Rosenblum JM, Wijetunga NA, Fazzari MJ, Krailo M, Barkauskas DA, Gorlick R, Greally JM. Predictive properties of DNA methylation patterns in primary tumor samples for osteosarcoma relapse status. Epigenetics 10(1):31-9, 2015. e-Pub 1/2015. PMCID: PMC4622015.

Reynolds CP, Kang MH, Maris JM, Kolb EA, Gorlick R, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program. Pediatr Blood Cancer 62(11):1897-905, 11/2015. e-Pub 7/2015. PMCID: PMC4758191.

Houghton PJ, Kurmasheva RT, Kolb EA, Gorlick R, Maris JM, Wu J, Tong Z, Arnold MA, Chatterjee M, Williams TM, Smith MA. Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 62(7):1214-21, 7/2015. e-Pub 3/2015. PMCID: PMC4563818.

Geller DS, Singh MY, Zhang W, Gill J, Roth ME, Kim MY, Xie X, Singh CK, Dorfman HD, Villanueva-Siles E, Park A, Piperdi S, Gorlick R. Development of a Model System to Evaluate Local Recurrence in Osteosarcoma and Assessment of the Effects of Bone Morphogenetic Protein-2. Clin Cancer Res 21(13):3003-12, 7/2015. e-Pub 12/2014. PMID: 25472999.

Kolb EA, Gorlick R, Keir ST, Maris JM, Kang MH, Reynolds CP, Lock RB, Carol H, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer 62(6):1106-9, 6/2015. e-Pub 11/2014. PMCID: PMC4405429.

Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, Lock RB, Keir ST, Maris JM, Billups CA, Lyalin D, Kurmasheva RT, Houghton PJ. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res 21(4):819-32, 2/2015. e-Pub 12/2014. PMCID: PMC4587665.

Smith MA, Hampton OA, Reynolds CP, Kang MH, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Kurmasheva RT, Wheeler DA, Houghton PJ. Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatr Blood Cancer 62(1):91-8, 1/2015. e-Pub 9/2014. PMCID: PMC4456187.